PISCATAWAY, NJ, September 27, 2004 - Sabinsa Corporation, a manufacturer and supplier of high quality herbal extracts, cosmeceuticals, minerals and specialty fine chemicals, today announced that an independent review conducted by CANTOX Health Sciences International confirms the safety of the company's ForsLean ingredient for use in dietary supplements.  ForsLean is a natural extract of Coleus forskohlii roots, the only known plant source of forskolin, a natural compound that increases lean body mass and optimizes body composition.  A letter issued by CANTOX states "the available information supports the safety of ForsLean® at the intake level of 500 mg per day resulting in a dose of 50 mg of forskolin."  CANTOX findings were based on scientific information and data, provided by Sabinsa Corporation and obtained from third-party literature, pertaining to the safety of ForsLean.       

"We allocate extensive time and resources to ensure that our products are properly tested for safety and efficacy and have funded several clinical studies involving ForsLean exclusively," stated Muhammed Majeed, founder and CEO, Sabinsa Corporation.  "This review by CANTOX further supports the safety of ForsLean brand Coleus forskohlii extract specifically and does not encompass generic Coleus alternatives."

In the conclusion of its review, CANTOX states "if serious side effects or adverse events had been suspected to be linked to forskolinŠone might expect reports of adverse effects in literature."  CANTOX notes that there have been no Adverse Effect Reports filed in association with forskolin.

Additionally, CANTOX asserts "clinical studies in which ForsLean® was administered at doses of up to 500 mg/day for periods of up to 12 weeks have demonstrated no significant effects on clinical chemistry or hematological parameters, nor any significant detrimental effects on blood pressure and thyroid function."

"Our ForsLean composition is one of the very few weight management ingredients currently available on the market that has gone through this type of rigorous independent, third party safety review," stated Todd Norton, president, Sabinsa Corporation.  "At a time when weight management products are under intense scrutiny, this should lay to rest any concerns regarding the safety of ForsLean for oral dosage use in dietary supplements at its clinically evaluated level."

ForsLean is a proprietary extract derived from Coleus forskohlii roots, a plant native to warm temperate habitats including India.  Coleus forskohlii is the only known plant source of forskolin, a natural compound that has been shown to increase lean body mass and help optimize body composition through cAMP activation.  Sabinsa holds U.S. Patent #5,804,596 (international patents pending) for the use of forskolin as a weight management ingredient and manufactures and supplies various extract strengths for use in a variety of supplements and products.  For more information visit www.forslean.com .

Sabinsa Corporation, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals.

Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being.  Over the past nine years, Sabinsa has brought to market more than thirty standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products.  With more than thirty scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market.  All products intended for human consumption are certified Kosher.

CANTOX Health Service International is a leading scientific consulting firm that specializes in developing scientific and global regulatory strategies, resolving toxicology and scientific issues and facilitating timely regulatory approvals for the food and dietary supplement industries.  CANTOX services include: ingredient and product safety assessments; expert scientific reviews; preparation of regulatory notifications and submissions [e.g., food additive and novel food petitions, natural health product (NHP) submissions, Generally Recognized As Safe (GRAS) and New Dietary Ingredient
(NDI) notifications]; dietary intake/exposure estimates; study protocol development and placement of non-clinical toxicology testing programs; monitoring and auditing of safety and clinical trials; substantiation of health-related claims; and facilitation of global regulatory approval.  For more information visit www.cantox.com .

Source:
Sabinsa Corporation

Contact:
Courtney Jacobs
Integrated Marketing Group
P: 801-538-0777 ext. 102
courtneyj@imgbranding.com